NCT06754501 2026-02-18A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryM.D. Anderson Cancer CenterPhase 2 Active not recruiting4 enrolled